

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1618

Deffez, Karine et al.

Examiner: Young, Micah Paul

INTERNATIONAL APPLICATION NO: PCT/EP03/11351

FILED: October 14, 2003

U.S. APPLICATION NO: 10/530856

35 USC §371 DATE: April 08, 2005

FOR: Deferacirox Dsipersible Tablets

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of May 26, 2010 has a shortened statutory time set to expire on August 26, 2010. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

The response to said Office Action is a request for filing a continued application of the above-identified application.

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1110 for payment of the extension fee. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,



Gregory Boughton
Attorney for Applicant
Reg. No. 47,666

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-2614

Date: 11/4/10